ERWINASE

Manufacturer:

Clinigen Group

Name:

ERWINASE

HCPCS Code Descriptor:

Injection, asparaginase (erwinaze), 1,000 iu

Category:

J Code

HCPCS:

J9019

NDC(s):

81561-0413-05

Primary Type:

Oncology

Generic/Specialty Status:

Single-Source

Route of Administration:

Injection

Potential NDC Listing Errors:

Our team has identified potential listing errors/discrepancies with the following NDCs:

81561-0413-05

About:

ERWINASE is an Oncology drug manufactured by Clinigen Group and administered via the Injection route of administration. The J Code: J9019 is aligned to the drug ERWINASE.

ERWINASE is an asparagine-specific enzyme derived from Erwinia chrysanthemi used to treat acute lymphoblastic leukemia (ALL). It is most often used as one part of a multi-therapeutic regimen for ALL. ERWINASE (J9019) works by catalyzing the deamination of asparagine in leukemic cells, depriving them of any asparagine and causing cell death since leukemic cells do not synthesize their own asparagine. It is indicated for patients who have developed hypersensitivity to E. coli derived asparagine.